Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Trading Up 0.6% – Should You Buy?

Shares of Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) were up 0.6% on Wednesday . The stock traded as high as $0.2958 and last traded at $0.2706. Approximately 5,383,457 shares traded hands during mid-day trading, an increase of 776% from the average daily volume of 614,526 shares. The stock had previously closed at $0.2691.

Calidi Biotherapeutics Stock Performance

The company has a 50-day moving average price of $0.47 and a two-hundred day moving average price of $1.05. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $3.00 million, a P/E ratio of -0.04 and a beta of 1.42.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last posted its quarterly earnings data on Friday, March 27th. The company reported $0.45 earnings per share for the quarter. On average, equities analysts forecast that Calidi Biotherapeutics, Inc. will post -4.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC raised its position in shares of Calidi Biotherapeutics by 41.7% in the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock worth $49,000 after acquiring an additional 12,334 shares in the last quarter. Warberg Asset Management LLC bought a new position in shares of Calidi Biotherapeutics in the 3rd quarter worth about $28,000. Virtu Financial LLC bought a new position in shares of Calidi Biotherapeutics in the 4th quarter worth about $25,000. Finally, DRW Securities LLC bought a new position in shares of Calidi Biotherapeutics in the 4th quarter worth about $173,000. 12.53% of the stock is owned by institutional investors.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.